Online citations, reference lists, and bibliographies.
← Back to Search

Drug Induced Movement Disorders

J. M. Velázquez-Pérez, C. Marsal-Alonso
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
INTRODUCTION Pharmaceutical preparations with the capacity to block dopamine receptors at the brain level quite often cause secondary movement disorders, but are not the only cause. These movement disorders can be due to a poor or difficult capacity to carry out movements similar to the type observed in idiopathic Parkinson's disease (parkinsonism secondary to drugs) or also because of excess movement with acute or chronic dystonic or choreic clinical pictures. Why the same drugs cause apparently opposing effects is not altogether clear, although it is supposed that individual factors related to the pharmacokinetics, pharmacodynamics and sensitivity of different types of sub-receptors play a crucial role. DEVELOPMENT We describe the most frequent groups of symptoms, divided into two parts depending on whether the disorder is hyper- or hypokinetic, and the drugs that are most commonly responsible for those clinical pictures are also discussed. The most frequent disorders caused by excessive movement are acute dyskinesia, akathisia and tardive dyskinesia. The disorder caused by scarcity of movement is a parkinsonian picture that it may be impossible to distinguish from idiopathic Parkinson's disease. CONCLUSIONS An awareness of the possible existence of these disorders is essential for the clinical suspicion and diagnosis. On most occasions, withdrawing the causing drug reverts the symptoms without the need for complicated or costly diagnostic studies.



This paper is referenced by
10.1007/s00406-014-0511-y
Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders
S. Potvin (2014)
10.1212/CON.0000000000000352
Diagnosis and Management of Dystonia
V. Shanker (2016)
10.5812/aapm.35333
Comparison of the Effects of Low-Dose Midazolam, Magnesium Sulfate, Remifentanil and Low-Dose Etomidate on Prevention of Etomidate-Induced Myoclonus in Orthopedic Surgeries
A. Sedighinejad (2016)
10.1186/s13023-020-01379-8
Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies
T. Opladen (2020)
10.14712/23362936.2020.1
Buspirone-associated Movement Disorder: A Literature Review.
J. Rissardo (2020)
10.1111/j.1468-3083.2008.02637.x
Oral manifestations of adverse drug reactions: guidelines
F. Femiano (2008)
10.1097/JCP.0000000000000411
Incidence of Oculogyric Crisis and Long-Term Outcomes With Second-Generation Antipsychotics in a First-Episode Psychosis Program
D. Gardner (2015)
10.1159/ISBN.978-3-8055-9801-9
Psychiatry of Parkinson's Disease
Klaus P. Ebmeier (2012)
10.5772/INTECHOPEN.78760
Tardive Dystonia due to D2 Antagonists and Other Agents
M. Skokou (2018)
10.1101/2020.12.22.424006
Cell-intrinsic effects of TorsinA(ΔE) disrupt dopamine release in a mouse model of DYT1-TOR1A dystonia
A. M. Downs (2020)
10.1111/ijpp.12650
Where are oral and dental adverse drug effects in product information?
L. Teoh (2020)
10.3390/ijms18020242
Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease
C. Comi (2017)
Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology
J. A. Borovac (2016)
10.1371/journal.pone.0050970
Antipsychotic-Induced Movement Disorders in Long-Stay Psychiatric Patients and 45 Tag SNPs in 7 Candidate Genes: A Prospective Study
P. Bakker (2012)
10.4172/2329-6895.1000259
Spectrum of Abnormal Movement in a Cohort of Neuro-Wilson Patients with Radiological Associations
M. Bagchi (2016)
10.1111/j.1479-8301.2011.00369.x
Polypharmacy increases the risk of Parkinson's disease in older people in Taiwan: A population‐based study
S. Lai (2011)
10.3389/fphar.2020.00596
The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use
I. Yunusa (2020)
10.1016/S1353-8020(13)70027-0
Acute and subacute drug-induced movement disorders.
P. Burkhard (2014)
10.1590/S0004-282X2008000100029
Chorea due to gabapentin monotherapy in a not encephalopatic patient.
C. A. Twardowschy (2008)
Extrapyramidové účinky léčiv – minimum pro farmaceuty
M. Baláž (2017)
10.1111/j.1600-0404.2008.01115.x
A double‐blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation
Z. Kefalopoulou (2009)
10.4103/tcmj.tcmj_13_20
Mirtazapine-associated movement disorders: A literature review
J. Rissardo (2020)
10.1371/journal.pone.0036561
Candidate Gene-Based Association Study of Antipsychotic-Induced Movement Disorders in Long-Stay Psychiatric Patients: A Prospective Study
P. Bakker (2012)
10.1371/journal.pone.0025588
Long-Stay Psychiatric Patients: A Prospective Study Revealing Persistent Antipsychotic-Induced Movement Disorder
P. Bakker (2011)
10.18203/2320-6012.IJRMS20164530
Comparative study of acupressure wristband versus palonosetron for prophylaxis of postoperative nausea and vomiting in elective laparoscopic cholecystectomy under general anaesthesia
Suchismita Naik (2016)
10.1111/ejn.14414
Maladaptive striatal plasticity and abnormal reward‐learning in cervical dystonia
Tom Gilbertson (2019)
10.7916/D8FJ2V9Q
Insights into Pathophysiology from Medication-induced Tremor
J. C. Morgan (2017)
10.1017/S1092852915000838
The clinical challenges of akathisia
J. Lohr (2015)
10.4137/JCNSD.S6561
Pharmacotherapy of Essential Tremor
P. Hedera (2013)
Caregivers of adults with intellectual disabilities: The relationship of compound caregiving and reciprocity to quality of life.
E. A. Perkins (2011)
10.1111/j.1440-1819.2008.01877.x
Postural induced‐tremor in psychiatry
B. Arbaizar (2008)
10.1136/jnnp.2006.100222
Movement disorders in patients taking anticonvulsants
C. Zadikoff (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar